Key Takeaways
- Trump administration is negotiating lower weight loss drug prices with pharmaceutical companies.
- A key stock valuation metric suggests market challenges ahead, mirroring the 1999 tech bubble.
- Lawmakers express cautious optimism about reaching a bipartisan deal to end the government shutdown.
- Former Vice President Dick Cheney has died at age 84, leaving a complex political legacy.
Deep Dive
- The Trump administration is negotiating with Eli Lilly and Novo Nordisk to lower weight loss drug prices on a government website, potentially including Medicare and Medicaid coverage.
- Novo Nordisk values obesity drug developer Matsera at $10 billion in a bidding war, surpassing Pfizer's $8.1 billion offer, highlighting the market's value.
- The Schiller Price-to-Earnings ratio, a stock valuation method using a decade of inflation-adjusted earnings, crossed 40 for the second time ever, mirroring the 1999 tech bubble peak.
- Spencer Jakab noted this ratio is a reliable indicator that accounts for inflation and business cycles, and its current high level predicts lower future returns.
- Research Affiliates suggests diversifying away from large U.S. tech companies like NVIDIA and Microsoft, as current market valuations indicate a potential pullback.
- The government shutdown is nearing a record for the longest in U.S. history, though a resolution appears possible as lawmakers are increasingly optimistic about a bipartisan deal.
- WSJ's Congress reporter Katy Stech Ferek noted the shutdown, which began October 1st, has furloughed federal workers, disrupted SNAP benefits, and led to airport delays.
- Senate members express optimism, but House Republicans face challenges due to conservative opposition to Democratic demands on healthcare funding, a condition for reopening the government.
- Former Vice President Dick Cheney passed away at age 84.
- Cheney defended the Bush administration's post-9/11 approach to the war on terror and advocated for the 2003 invasion of Iraq.
- He later became a conservative critic of both the Obama administration and Donald Trump, notably endorsing Kamala Harris in 2024.